← Back to Clinical Trials
Recruiting Phase 3 NCT06301412

NCT06301412 Combination of Hypothermia and Thrombectomy in Acute Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06301412
Status Recruiting
Phase Phase 3
Sponsor University of Freiburg
Condition Ischemic Stroke
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2024-07-07
Primary Completion 2026-03-18

Trial Parameters

Condition Ischemic Stroke
Sponsor University of Freiburg
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 400
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-07-07
Completion 2026-03-18
Interventions
hypothermia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion. The main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed. Researchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.

Eligibility Criteria

Inclusion Criteria: * Pre-stroke modified Rankin Scale (mRS) 0-2 \[7-point scale rating from 0 (no symptoms) to 6 (dead)\] * Acute ischemic stroke with NIHSS \>5 * Intracranial occlusion of the M1 or M2 segment of the middle cerebral artery (MCA) or internal carotid artery (ICA) or tandem occlusion on CT-angiography or MR-angiography with indication for endovascular treatment: * Time window 0-24h: 1. Last seen normal to groin puncture \< 6h: native CT or MRI-DWI with ASPECTS \>5 2. Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial * Infarct core \<70ml (DWI oder CBF\<30%) * Penumbra \> 15ml (Tmax \>6sec) * Ratio penumbra/core \>1.8 * with or without iv thrombolysis with rtPA Exclusion Criteria: * Patients with an intranasal obstruction that prevents complete insertion of the nasal cannula should not be treated with the RhinoChill system. * Known severe hemorrhagic diathesis (Internat

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology